FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

Amgen Inc. today announced that the U.S. FDA has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor.

The details can be read here.